(RS)-KETOPROFEN
Fibrosis
M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
1 Active assets in the Fibrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
N-Acetyl-L-Cysteine University of Guadalajara | Phase 2 | B |
PRAVASTATIN M.D. Anderson Cancer Center | Phase 2 | CCC |
Same molecule, other indications
(RS)-KETOPROFEN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →